Results 11 to 20 of about 407,619 (292)

Access to precision medicine in Thailand: a comparative study [PDF]

Journal of Health Research, 2022
Purpose – This study explored health insurance coverage of genetic testing and potential factors associated with precision medicine (PM) reimbursement in Thailand. Design/methodology/approach – The study employed a targeted review method.
Nisita Jirawutkornkul, Chanthawat Patikorn, Puree Anantachoti   +2 more
doaj   +1 more source

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines

Journal of Market Access & Health Policy, 2017
Introduction: Health technology assessment (HTA) in Poland supports reimbursement decisions via the Polish HTA Agency (AOTMiT), whose guidelines were updated in 2016.
Krzysztof Lach, Michal Dziwisz, Cécile Rémuzat, Mondher Toumi   +3 more
doaj   +1 more source

Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security

Cost Effectiveness and Resource Allocation, 2019
Background To estimate the incremental cost-effectiveness ratio (ICER) of the use of continuous subcutaneous insulin infusion (CSII) therapy versus multiple daily injections (MDI) therapy in adult patients with type 1 diabetes (T1D) at the Mexican ...
Svetlana V. Doubova, Stephane Roze, Aldo Ferreira-Hermosillo, Ricardo Pérez-Cuevas, Ricardo Gasca-Pineda, Casper Barsoe, Jonathan Baran, Brian Ichihara, Erick Gryzbowski, Kyla Jones, Juan E. Valencia   +10 more
doaj   +1 more source

Comparison of Cardiovascular Medicines Prices in Four European Countries

Frontiers in Public Health, 2020
The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-
Zornitsa Mitkova, Mariya Vasileva, Alexandra Savova, Alexandra Savova, Manoela Manova, Manoela Manova, Silvia Terezova, Silvia Terezova, Guenka Petrova   +8 more
doaj   +1 more source

“Ready for the future?” – Status of national and cross-country horizon scanning systems for medicines in European countries

GMS German Medical Science, 2022
Background: Horizon scanning aims to systematically identify upcoming health technologies and thus allows policy-makers to be better prepared for the entry of new medicines with possibly high price tags into the national health system.
Vogler, Sabine
doaj   +1 more source

Why licensing authorities need to consider the net value of new drugs in assigning review priorities: Addressing the tension between licensing and reimbursement [PDF]

, 2008
Pharmaceutical regulators and healthcare reimbursement authorities operate in different intellectual paradigms and adopt very different decision rules. As a result, drugs that have been licensed are often not available to all patients who could benefit ...
Angell, Anthony O'Hagan, Brazier, Christopher McCabe, Detels, Drummond, Karl Claxton   +6 more
core   +1 more source

A comparative study of orphan drug prices in Europe

Journal of Market Access & Health Policy, 2017
Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK.
Katherine Eve Young, Imen Soussi, Michiel Hemels, Mondher Toumi   +3 more
doaj   +1 more source

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries

Frontiers in Public Health, 2018
BackgroundPolicy makers face a lot of challenges in the process of drug reimbursement decision-making, especially in the context of entering the market of more and more innovative medicinal products (MPs).
Maria Kamusheva, Mariya Vassileva, Alexandra Savova, Alexandra Savova, Manoela Manova, Manoela Manova, Guenka Petrova   +6 more
doaj   +1 more source

A comparison of reimbursement recommendations by European HTA agencies : Is there opportunity for further alignment? [PDF]

, 2017
Introduction: In Europe and beyond, the rising costs of healthcare and limited healthcare resources have resulted in the implementation of health technology assessment (HTA) to inform health policy and reimbursement decision-making.
Allen, Allen, Allen, Bending, Drummond, Drummond, Henshall, Kleijnen, Kristensen, Morton, Nicod, Ruof, Velasco-Garrido, Łanda   +13 more
core   +3 more sources

Workforce requirements for comprehensive ischaemic stroke care in a developing country: the case of Saudi Arabia

Human Resources for Health, 2019
Background Ischaemic stroke care requires a co-ordinated multi-disciplinary approach to optimise patient outcomes. Current care provision in Saudi Arabia is below international recommendations, and with increasing patient numbers, variable access to new ...
Fahmi Al-Senani, Mohammad Salawati, Mohammed AlJohani, Matthieu Cuche, Valeska Seguel Ravest, Simon Eggington   +5 more
doaj   +1 more source